UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
February 23, 2006
Date of Report (Date of earliest event reported)
NPS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 0-23272 | 87-0439579 | ||
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification Number) |
383 Colorow Drive
Salt Lake City, Utah 84108
(Address of principal executive offices)
(801) 583-4939
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 Other Events.
On February 23, 2006, NPS Pharmaceuticals and its partner Nycomed Danmark ApS issued press releases announcing that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMEA, has adopted a positive opinion recommending authorization for Nycomed to market Preotact® in the European Union. Preotact® is the European brand name for PREOS® which NPS licensed to Nycomed in 2004 for development and marketing in Europe. The CHMP recommendation is the last step prior to receipt of marketing authorization by the EMEA. A copy of the NPS press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
| (c) | Exhibits |
| 99.1 | Press Release issued by the Company on February 23, 2006. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: February 23, 2006 | NPS PHARMACEUTICALS, INC. | |||
| By: | /s/ KEVIN J. ONTIVEROS | |||
Kevin J. Ontiveros Associate General Counsel and Assistant Corporate Secretary | ||||
EXHIBIT INDEX
| Exhibit Number | Description | |
| 99.1 | Press Release issued by NPS Pharmaceuticals, Inc. on February 23, 2006. | |
